These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39007143)

  • 1. Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood.
    Alakhras NS; Moreland CA; Wong LC; Raut P; Kamalakaran S; Wen Y; Siegel RW; Malherbe LP
    Front Immunol; 2024; 15():1354055. PubMed ID: 39007143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate Immune Sensing of Adeno-Associated Virus Vectors.
    Cao D; Byrne BJ; de Jong YP; Terhorst C; Duan D; Herzog RW; Kumar SRP
    Hum Gene Ther; 2024 Jul; 35(13-14):451-463. PubMed ID: 38887999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
    Zhu J; Huang X; Yang Y
    J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG-depleted adeno-associated virus vectors evade immune detection.
    Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
    J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I IFN Sensing by cDCs and CD4
    Shirley JL; Keeler GD; Sherman A; Zolotukhin I; Markusic DM; Hoffman BE; Morel LM; Wallet MA; Terhorst C; Herzog RW
    Mol Ther; 2020 Mar; 28(3):758-770. PubMed ID: 31780366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.
    Martino AT; Suzuki M; Markusic DM; Zolotukhin I; Ryals RC; Moghimi B; Ertl HC; Muruve DA; Lee B; Herzog RW
    Blood; 2011 Jun; 117(24):6459-68. PubMed ID: 21474674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors.
    Xicluna R; Avenel A; Vandamme C; Devaux M; Jaulin N; Couzinié C; Le Duff J; Charrier A; Guilbaud M; Adjali O; Gernoux G
    Hum Gene Ther; 2024 May; 35(9-10):355-364. PubMed ID: 38581431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of CpGs in AAV gene therapy vectors induces a plasmacytoid dendritic cell-like population very early after administration.
    Glenn JD; Negash H; Henry W; Qian R; Liu Y; Danos O; Bruder JT; Karumuthil-Melethil S
    Cell Immunol; 2024; 399-400():104823. PubMed ID: 38520831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants.
    Emmanuel SN; Smith JK; Hsi J; Tseng YS; Kaplan M; Mietzsch M; Chipman P; Asokan A; McKenna R; Agbandje-McKenna M
    J Virol; 2022 Feb; 96(3):e0125121. PubMed ID: 34757842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer.
    Rogers GL; Suzuki M; Zolotukhin I; Markusic DM; Morel LM; Lee B; Ertl HC; Herzog RW
    J Innate Immun; 2015; 7(3):302-14. PubMed ID: 25612611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.
    Hamilton BA; Wright JF
    Front Immunol; 2021; 12():675897. PubMed ID: 34084173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8
    Rogers GL; Shirley JL; Zolotukhin I; Kumar SRP; Sherman A; Perrin GQ; Hoffman BE; Srivastava A; Basner-Tschakarjan E; Wallet MA; Terhorst C; Biswas M; Herzog RW
    Blood; 2017 Jun; 129(24):3184-3195. PubMed ID: 28468798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.
    Kuranda K; Jean-Alphonse P; Leborgne C; Hardet R; Collaud F; Marmier S; Costa Verdera H; Ronzitti G; Veron P; Mingozzi F
    J Clin Invest; 2018 Dec; 128(12):5267-5279. PubMed ID: 30352429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extra-viral DNA in adeno-associated viral vector preparations induces TLR9-dependent innate immune responses in human plasmacytoid dendritic cells.
    Bucher K; Rodríguez-Bocanegra E; Wissinger B; Strasser T; Clark SJ; Birkenfeld AL; Siegel-Axel D; Fischer MD
    Sci Rep; 2023 Feb; 13(1):1890. PubMed ID: 36732401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Context-Specific Function of the Engineered Peptide Domain of PHP.B.
    Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM
    J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of naturally-occurring humoral immunity to AAV in sheep.
    Tellez J; Van Vliet K; Tseng YS; Finn JD; Tschernia N; Almeida-Porada G; Arruda VR; Agbandje-McKenna M; Porada CD
    PLoS One; 2013; 8(9):e75142. PubMed ID: 24086458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy.
    Ashley SN; Somanathan S; Giles AR; Wilson JM
    Cell Immunol; 2019 Dec; 346():103997. PubMed ID: 31703913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.